Navigation Links
drugstore.com Reports Highest Net Revenues in Company History
Date:4/29/2009

the active customer base (a trailing 12-month number) and average annual spend per active customer exclude net sales and orders generated by the company's CNS fulfillment relationship with Weil, and reflect only the activity of customers making purchases through the Web sites of drugstore.com, inc. and its subsidiaries.

Conference Call

Investors, analysts, and other interested parties are invited to join the drugstore.com, inc. quarterly conference call on April 29, 2009 at 5:00 p.m. ET (2:00 p.m. PT). To participate, callers should dial 866-250-2351 (international callers should dial 303-262-2130) five minutes beforehand. Investors may also listen to the conference call live at http://investor.drugstore.com/, by clicking on the "audio" hyperlink. A replay of the call will be available through Friday, May 1, 2009 by dialing 800-405-2236 (enter pass code 11130228#) or internationally at 303-590-3000 (enter pass code 11130228#) beginning two hours after completion of the call.

Non-GAAP Measures

To supplement the consolidated financial statements presented in accordance with GAAP, drugstore.com, inc. uses the non-GAAP measure of adjusted EBITDA, defined as earnings before interest, taxes, depreciation, and amortization of intangible assets and non-cash marketing expenses, adjusted to exclude the impact of stock-based compensation expense. This non-GAAP measure is provided to enhance the user's overall understanding of the company's current financial performance. Management believes that adjusted EBITDA, as defined, provides useful information to the company and to investors by excluding certain items that may not be indicative of the company's core operating results. In addition, because drugstore.com, inc. has historically provided adjusted EBITDA measures to investor
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. drugstore.com and Revolution Health Group Announce Breakthrough Deal
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
4. drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
5. drugstore.com, inc. to Present at the Upcoming Jefferies 4th Annual Internet Conference and the Morgan Stanley Technology Conference
6. drugstore.com, inc. to Announce First Quarter 2008 Results During Conference Call on Monday, May 5, 2008 at 5:00 p.m. ET
7. drugstore.com inc. Reports Results for the First Quarter of 2008
8. drugstore.com, inc. to Present at Upcoming Investor Conferences
9. drugstore.com inc. Reports Solid Revenue Growth and Record Gross Margins in the Third Quarter of 2008
10. drugstore.com Offers Free Shipping to U.S. Troops Serving Overseas and in the United States
11. drugstore.com Announces Strategic Alliance With Medco Health Solutions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...re open on-the-job interaction might ease the prob... (HealthDay News) -- Men who bottle up their anger...eir hearts, a new Swedish study indicates. , Me...ent over conflicts with a fellow worker or supervi... attack or die of heart disease as those who vente...
(Date:11/23/2009)...,, ClinicsContinuetoTargetIndividualsintheRecom.../PRNewswire-USNewswire/--TheDepartmentofHealthanno...ationclinicsatlocalStateHealthCentersinDelaware,La...sday,Nov.25.TheH1N1vaccinewillbeadministeredforfre...nothadpreviousaccesstothevaccine.Thedepartmentasks...
(Date:11/23/2009)...Three quarters of cancer patients and survivors tr...isorders that often become chronic conditions, hin...ng to scientists at the University of Rochester Me...howed they experienced sleep troubles at nearly th...problem was more prevalent in younger patients and...
(Date:11/23/2009)...NEW YORK (Nov. 23, 2009) -- A first-of-its-kind co... online today in the Annals of Surgery . The repo...onal consensus conference -- Diabetes Surgery Summ...han 50 scientific and medical experts agreed on a ...hat are meant to guide the use and study of gastro...
(Date:11/23/2009)...rtnerships doubled number of patients who reined i...MONDAY, Nov. 23 (HealthDay News) -- High blood pre...ams working hand-in-hand than by doctors and pharm...n physicians work with pharmacists, medications ar... more effectively," said Barry L. Carter, a profes...
Breaking Medicine News(10 mins):Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 3Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 4Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 5Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3
... be enough to prevent the loss of vision and even ... a new study has shown. When researchers ... wild salmon, sardines, anchovies and other coldwa...enetically-modified lab rodents showed no ill side...
... bmj.com today (Tuesday 26 June) questions the val... well-controlled, non-insulin dependent (type 2) d...ay at the American Diabetes Association Conference...y develops in people over 40, especially when the ...
... Benoit killed his wife and young son over the wee... World Wrestling Entertainment, Inc. has reporte...Chris, Nancy, and seven-year-old Daniel in their h... that the deaths were the result of a double murde...
...l Radcliffe, Emma Watson and Rupert Grint admit th...t their age do - drinking and smoking . Ho...of other young stars, is that they maintain their ...s that unlike a lot of young stars, the trio didn'...
...hat a class of commonly prescribed antidepressants...n older men and women . The antidepressant... inhibitors (SSRIs) treat depression by inhibiting...which has recently been discovered in bone as well...
...illegal drugs has said that opium production in Af...World Drug Report says over 90 percent of illegal ...ghanistan. According to a BBC report, the...t Afghanistan is unlikely to regain real security ...
Other Medicine News:Health News:Eating Fish Oil can Save Eyesight: Study 2Health News:Questions Over Value of Glucose Monitoring for Non-insulin Using Diabetes Patients 2Health News:Common Antidepressants Linked to Increased Bone Loss in Older Adults 2Health News:Common Antidepressants Linked to Increased Bone Loss in Older Adults 3
(Date:11/23/2009)...tCall/--AccurayIncorporated(Nasdaq: ARAY ),aglobal...tsmanagementisscheduledtopresentatthe21stAnnualPip...cember1,2009at9:00a.m.ET/6:00a.m.PT.Thecompanywill...NewYorkonThursday,December3,2009at3:00p.m.ET/12:00...availableonlinefromtheinvestorrelationspageoftheCo...
(Date:11/23/2009)...FirstCall/--TransceptPharmaceuticals,Inc.(Nasdaq: ...U.S.FoodandDrugAdministration(FDA)onJanuary20,2010...rugApplication(NDA)for Intermezzo ® (zolpide...heCompleteResponseLetter,receivedbyTransceptonOcto...Ainitspresentform.TheNDAseeksapprovaltomarket Inte...
(Date:11/23/2009)...r.comannouncesthatanewmarketresearchreportisavaila...ImagingMarketto2015 ,, http://www.reportlink...ng-Market-to-2015.html#utm_source=prnewswire&u... Description ,, TheFutureoftheDiagnosticImagi...Direct,s"TheFutureoftheDiagnosticImagingMarketto20...
Breaking Medicine Technology:Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference 2Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 2Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 3Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 4Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 5Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 6Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 7Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 8Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 9Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 10Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 11Cardio Vascular Medical Device to Apply for Additional Patents in Europe Canada and Far East 61861 1Cardio Vascular Medical Device to Apply for Additional Patents in Europe Canada and Far East 61861 2Nevada Health Care Association 28NHCA 29 Supports Majority Leader Reid 61859 1Veridiam Wins Workplace Excellence Crystal Award in Mid Size Company Category 14935 1Veridiam Wins Workplace Excellence Crystal Award in Mid Size Company Category 14935 2
...orted Trial Enrollment Advancing Ahea...1 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) ... company,s ongoing Phase 2 clinical trial of its l...), in platinum-resistant ovarian,cancer patients a...ASCO),Annual Meeting in Chicago, Illinois., "Vore...
..., COLLEGEVILLE, Pa., May 31 Wyeth,Pharmaceutical...ced results,of a three-arm phase 3 clinical trial ... mantle cell lymphoma (MCL), a form of non-Hodgkin...et of rapamycin) inhibitor,TORISEL(R) (temsirolimu...ment in median progression-free survival (PFS), co...
Other Medicine Technology:Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6
Bone Rongeur
Husk Rongeurs
Horsley Bulldog Bone Rongeur
Smith-Petersen Laminectomy Bone Rongeurs
Medicine Products: